以特瑞普利单抗为代表的抗PD-1单抗联合吉西他滨+顺铂(GP)方案已成为R/M NPC患者的一线标准治疗方案。然而顺铂毒性较大，存在部分患者由于肾功能受损、体力状况较差、听力丧失或心力衰竭等原因无法耐受顺铂治疗。特瑞普利单抗已经相继在中国、美国、欧盟获批用于治疗R/M NPC。考虑到长期疗效和低毒性特征，本研究假设特瑞普利单抗联合毒性较小的化疗药物(吉西他滨)有望在不降低疗效的前提下提高安全性，最终达到去铂目的。On November 6, junshi bio (01877) announced that the latest data from the phase 2 study of teprilumab combined with JS-001 as a first-line treatment for platinum-resistant R/M NPC patients with relapsed/metastatic nasopharyngeal carcinoma (R/M NPC) was published in the international journal Cell Reports Medicine.
According to the Securities Times APP, on November 6, junshi bio (01877) announced that the latest data from the phase 2 study of teprilumab combined with JS-001 as a first-line treatment for platinum-resistant R/M NPC patients with relapsed/metastatic nasopharyngeal carcinoma (R/M NPC) was published in the international journal Cell Reports Medicine.
The results of the study showed an objective response rate (ORR) of 61.9%, a disease control rate (DCR) of 100%, a median progression-free survival (PFS) of 11.8 months, and significantly reduced toxicity compared to standard platinum-based treatments, with only 23.8% of patients experiencing grade ≥3 adverse events (AE). Junshi bio's press release stated that this treatment regimen has comprehensively optimized and upgraded the efficacy and safety for R/M NPC patients resistant to platinum-based treatments.
The anti-PD-1 monoclonal antibody therapy represented by teprilumab combined with JS-001 + platinum (GP) regimen has become the first-line standard treatment for R/M NPC patients. However, platinum-based treatment is highly toxic, and some patients are unable to tolerate it due to impaired renal function, poor physical condition, hearing loss, or heart failure. Teprilumab has been successively approved for the treatment of R/M NPC in China, the USA, and the EU. Considering its long-term efficacy and low toxicity profile, this study hypothesized that teprilumab combined with less toxic chemotherapy (JS-001) could potentially enhance safety without compromising efficacy, ultimately achieving the goal of platinum elimination.
